

Self-Association of the glycan antibiotic teicoplanin A2 in aqueous solution studied by molecular hydrodynamics

CHUN, T., PATTEM, J, GILLIS, Richard <<http://orcid.org/0000-0002-7607-6808>>, DINU, V.T., YAKUBOV, G.E., CORFIELD, A.P. and HARDING, S.

Available from Sheffield Hallam University Research Archive (SHURA) at:

<https://shura.shu.ac.uk/31154/>

This document is the Pre-print

Citation:

CHUN, T., PATTEM, J, GILLIS, Richard, DINU, V.T., YAKUBOV, G.E., CORFIELD, A.P. and HARDING, S. (2022). Self-Association of the glycan antibiotic teicoplanin A2 in aqueous solution studied by molecular hydrodynamics. [Pre-print] (Unpublished) [Pre-print]

Copyright and re-use policy

See <http://shura.shu.ac.uk/information.html>

Self-Association of the glycan antibiotic teicoplanin A2 in aqueous solution studied by molecular hydrodynamics

Taewoo Chun

University of Nottingham

Jacob Patten

University of Nottingham

Richard B. Gillis

University of Nottingham

Vlad T. Dinu

University of Nottingham

Gleb E. Yakubov

University of Nottingham

Anthony P. Corfield

University of Nottingham

Stephen Harding (✉ steve.harding@nottingham.ac.uk)

University of Nottingham

Article

Keywords:

Posted Date: November 9th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-2223619/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Self-Association of the glycan antibiotic teicoplanin A2 in aqueous solution studied by molecular hydrodynamics

Taewoo Chun¹, Jacob Pattem^{1,2}, Richard B. Gillis^{1,2}, Vlad T. Dinu¹, Gleb E. Yakubov^{2,3}, Anthony P. Corfield¹, Stephen E. Harding^{1*}

1: National Centre for Macromolecular Hydrodynamics, University of Nottingham, Sutton Bonington LE12 5RD United Kingdom.; 2: Biomaterials Group, School of Biosciences, University of Nottingham, Sutton Bonington, LE12 5RD, United Kingdom. 3: ARC Centre of Excellence in Plant Cell Walls, School of Chemical Engineering, The University of Queensland, St. Lucia, Brisbane, QLD 4072, Australia.

*Corresponding author: steve.harding@nottingham.ac.uk

Abstract

The semi-synthetic glycan antibiotic teicoplanin is used for the treatment of serious Gram-positive related bacterial infections and can be administered intravenously, intramuscularly, topically (ocular infections), or orally. It has also been considered for targeting viral infection by SARS-CoV-2. The hydrodynamic properties of teicoplanin A2 (monomer molar mass ~ 1880 g/mol) were examined in phosphate chloride buffer (pH 6.8, $I = 0.10$ M) using sedimentation velocity and sedimentation equilibrium in the analytical ultracentrifuge together with capillary (rolling ball) viscometry. In the concentration range, 0-10 mg/mL teicoplanin A2 was found to self-associate plateauing > 1 mg/mL to give a molar mass of (35400 ± 1000) g/mol corresponding to $\sim (19 \pm 1)$ mers, with a sedimentation coefficient $s_{20,w} = \sim 4.65$ S. The intrinsic viscosity $[\eta]$ was found to be (3.2 ± 0.1) mL/g: both this, the value for $s_{20,w}$ and the hydrodynamic radius from dynamic light scattering is consistent with a globular macromolecular assembly, with a swelling ratio through dynamic hydration processes of ~ 2 .

Introduction

Teicoplanin is a member of the glycopeptide antibiotic family, such as vancomycin, to treat severe bacterial infections. This glycopeptide antibiotic was first extracted from *Actinoplanes teichomyceticus*, which was discovered in 1978 from an Indian soil sample¹. Its main chemical structure (Figure 1) is a heptapeptide with three monosaccharide residues: α -D-mannose, *N*-acetyl- β -D-glucosamine, and *N*-acetyl- β -D-glucosamine^{2,3}. For teicoplanin, there are six major subtypes (A2-1 through A2-5, and A3-1) and four minor subtypes (from RS-1 to RS-4)⁴. Of these subtypes, teicoplanin is primarily formed by bacteria as a blend of A2-1 through A2-5 lipofoms which have different fatty acid chains attached to the glcNAc (*N*-acetyl- β -D-glucosamine) residue⁵. The antibiotic mechanism teicoplanin is similar to another glycopeptide vancomycin (structurally similar, although not containing lipid), and both antibiotics inhibit the formation of the peptidoglycan chains of bacterial cell walls, by attaching to the D-Ala-D-Ala C-terminus of the pentapeptide substrate via hydrogen bonds⁶. Moreover, teicoplanin is

known to interact with this pentapeptide substrate through its hydrophobic lipid chain, resulting in the positioning of the antibiotic being adjacent to the peptidoglycan^{7,8}.

Teicoplanin is used in the treatment of life-threatening infectious diseases caused by multidrug-resistant Gram-positive bacteria, including methicillin-resistant *Staphylococcus aureus* (MRSA) and *Enterococci*. Teicoplanin has a proven, outstanding high efficacy in various tissue sites, such as the heart and respiratory tracts⁹. Its main routes of administration are intravenous and intramuscular, although it is also given orally and is considered for topical administration, especially for treating ocular infections

The therapeutic plasma concentration of teicoplanin ranges from 10 to 30 mg/L, depending on the severity of the disease or the range of infectious sites, for example, bone infections^{10–12}, and has been found to bind to serum albumin in the blood¹⁰. On the other hand, oral and topical (ocular infections) administrations are limited. The oral route is used for the treatment of pseudomembranous colitis caused by *Clostridium difficile*¹³. In terms of ocular infections, Kaye suggested synergistic benefits of teicoplanin with other antibiotics, such as meropenem, against *S. aureus* keratitis^{14,15}, although Kaye's research group concluded that there was little penetration of teicoplanin into human aqueous humour below the cornea with the administration of 10 mg/mL eye drops¹⁶. Antoniadou et al. also reported a similar result: no penetration into the aqueous humour, with the subconjunctival injection (approximately 0.5 mL) of 25 mg teicoplanin¹⁷.

Since the beginning of the Covid-19 pandemic in December 2019, teicoplanin has been spotlighted as a potential drug candidate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) due to its well-known antiviral ability. Zhou and colleagues had earlier indicated that teicoplanin inhibited cell entry of the SARS-CoV virus¹⁸. In order to cross the cell membrane and enter a host cell, both SARS-CoV and SARS-CoV-2 viruses depend on cysteine proteinase cathepsin L (CTSL), which splits viral spike (S) glycoproteins attached to a host receptor so that viruses are released from an endosome within the host cell^{18,19}. The fatty acid chain of teicoplanin interacts with CTSL, while vancomycin, without such a hydrophobic group, cannot express antiviral activity against CTSL-dependent viruses¹⁸. Consequently, some clinical studies were focused on the novel medical use of teicoplanin as a Covid-19 drug^{20,21}. Regardless of whether teicoplanin is used in the treatment of Covid-19 or co-infections of Gram-positive bacteria in Covid-19 patients, its use is still in demand.

However, there has been a growing concern about the resistance to teicoplanin in pathogens since its approval in Europe in 1988. In the same year, it was already shown that vancomycin- and teicoplanin-resistant *Enterococci* strains had been isolated from patients in France²². Gram-positive bacteria, especially *Enterococci*, acquire resistance by modifying their D-Ala-D-Ala moiety of peptidoglycan precursors, Lipid II. This moiety is transformed to either D-Ala-D-Lac (*vanA*, *vanB*, *vanD*) or D-Ala-

D-Ser (*vanC*, *vanE*, *vanG*) in resistant strains, and as a result, glycopeptides have a low affinity to these phenotypes of precursors^{23,24}.

Although it is important to explore how teicoplanin binds to the Lipid II moiety regardless of its phenotypes, the knowledge of the biological form of teicoplanin in an aqueous solution is of importance. It is known that the minimum volume of solvent required to dissolve 400 mg of teicoplanin is 3 ml because, below that value, a gel might be formed in solution¹⁰. This gelation/coalescence of teicoplanin was thought to be caused by micellization due to its hydrophobic tail^{25,26}, although a teicoplanin derivative without that tail can still aggregate in solution²⁷. This concentration-dependent aggregation might lead to poor permeability of teicoplanin across the epithelial lining by the oral and topical (ocular) routes, and additionally, the aggregated form may be responsible for excessive exposure of teicoplanin, resulting in more bacteria acquiring resistance. Due to its importance, in this study, we perform an analysis of this associative/aggregation effect using the powerful hydrodynamic techniques of sedimentation velocity and sedimentation equilibrium in the analytical ultracentrifuge (SV-AUC, SE-AUC) taking advantage of the inherent separation and analysis facilities of the analytical ultracentrifuge (AUC). Analytical ultracentrifugation is a matrix-free method with a broad range of molar masses, 10^2 - 10^8 g/mol, and the key technique used to explore the molecular behaviours of proteins, polysaccharides, or other macromolecules in solution²⁸. AUC has recently been used to characterize the self-associative properties of vancomycin²⁹ and its interactions with VanS³⁰ and mucins³¹.

We then also assess the solution conformation of the association/aggregation products using molecular viscometric analysis of the intrinsic viscosity $[\eta]$, in combination with the sedimentation coefficient from sedimentation velocity. We believe this present study is the first report demonstrating the self-association of teicoplanin with hydrodynamic methods.

Materials and Methods

Teicoplanin

Teicoplanin A2 (monomer molar mass: $M_1 = 1877.6$ g/mol for teicoplanin A2-1, $M_1 = 1879.7$ g/mol for teicoplanin A2-2 and A2-3, and $M_1 = 1893.7$ g/mol for teicoplanin A2-4 and A2-5) was purchased in powder form from Sigma-Aldrich, United Kingdom. Its structure is shown in Figure 1:




Figure 1. Structure of teicoplanin (adapted from the National Institute for Health/ National Center of Biotechnology Information³² based on an original structure given by F. Parenti³³). Teicoplanin lipoforams A2-2 ($M_1 = 1879.7$ g/mol) is shown: the other major lipoforams of A2 with different acyl chains are shown in the inset

Teicoplanin samples were prepared in a phosphate-chloride buffered saline solution (PBS, or “Paley buffer”) at pH~6.8 and, by adding NaCl, adjusted to an ionic strength of $I = 0.1$ mol/L³⁴.

The concentration, c (g/mL) of the stock solution was then measured using a differential refractometer (Atago DD7, Tokyo, Japan) set to zero with the reference solvent (PBS) and using a refractive increment dn/dc of 0.188 mL/g for teicoplanin³⁵. The measured concentration was multiplied by 0.96 for moisture

content correction, being calculated from the difference in the weights of teicoplanin powder before and after the vacuum oven (Vacuum Oven 31 litres, Fistreem, Cambridge, UK) drying overnight³⁶.

The partial specific volume \bar{v} from solution/ solvent densities was determined using an Anton-Paar (Graz, Austria) digital density meter³⁷, and application of:

$$\bar{v} = \frac{1}{\rho_0} \cdot \left(1 - \frac{\rho - \rho_0}{c}\right) \quad (1)$$

at a concentration, c , of 10.2 mg/mL, and where ρ and ρ_0 are the densities of the solution and solvent, respectively. A value of (0.64 ± 0.01) mL/g, was obtained, similar to that for vancomycin²⁹.

Sedimentation velocity in the analytical ultracentrifuge

Experiments to determine sedimentation coefficients and sedimentation coefficient distributions were performed at a temperature of 20.0 °C using an Optimal XL-I analytical ultracentrifuge (Beckman Instruments, Palo Alto, CA, USA) with Rayleigh interference optics. Teicoplanin samples (400 μ L) and reference solvent (PBS, 420 μ L) were injected into channels of the 12 mm double sector epoxy cells with sapphire windows. These cells were then centrifuged at 47500 rpm for a run time of ~24 h and the data obtained were analysed in SEDFIT using the least squares, ls-g*(s) processing method³⁸. This generates the sedimentation coefficient distribution, $g(s)$ versus $s_{T,b}$, where $s_{T,b}$ is the sedimentation coefficient, at temperature T in buffer b . The s value in Svedberg units, $S = 10^{-13}$ seconds, was then normalised to standard conditions (density $\rho_{20,w}$ and viscosity $\eta_{20,w}$ of water at 20.0 °C) to give $s_{20,w}$ from the equation³⁹:

$$s_{20,w} = \frac{1 - \bar{v} \cdot \rho_{20,w}}{1 - \bar{v} \cdot \rho_{T,b}} \cdot \frac{\eta_{T,b}}{\eta_{20,w}} \cdot s_{T,b} \quad (2)$$

where $\rho_{T,b}$ and $\eta_{T,b}$ are the density and the viscosity of buffer b at temperature T , respectively.

Sedimentation equilibrium in the analytical ultracentrifuge

Due to the longer time required compared to sedimentation velocity, sedimentation equilibrium experiments were performed at a temperature of 7.0 °C also using the Optimal XL-I analytical ultracentrifuge to obtain equilibrium concentration distribution profiles. To characterise the self-association/aggregation of teicoplanin, 12 mm double sector epoxy cells were loaded with the same volumes (100 μ L) of both solution and solvent and run at 45000 rpm for a run time of ~48 h. Lower experiment temperature stabilised samples. Records of concentration distributions of teicoplanin at

equilibrium were subsequently analysed using the model-independent SEDFIT-MSTAR algorithm⁴⁰. Since the non-ideality of teicoplanin is negligible we estimated that apparent weight average molar masses $M_{w,app}$ were approximately equal to the true weight average molar masses M_w ⁴¹.

Hydrodynamic radius determination by dynamic light scattering (DLS)

Dynamic or quasi-elastic light scattering (DLS or QLS) measurements were made on the fixed scattering angle Zetasizer Nano-S system (Malvern instruments Ltd., Malvern UK) equipped with a 4mW He-Ne laser at a wavelength of 632.8nm^{42,43}. Samples in solution were measured in a quartz cuvette at 20.0°C. A scattering angle of 173° was used, and collected in manual mode, requiring a measurement duration of 90 seconds. The resulting data were analysed using the “Zetasizer Software (Version 7.1)” (Malvern Instruments Ltd., Malvern, UK), providing a volume distribution of translational diffusion coefficients based on a form of the CONTIN program⁴⁴. The viscosity of the buffer used was calculated using a solvent builder interface and takes the effects of buffer salts into account. The z-average hydrodynamic radii r_z (nm), were evaluated from the z-average translational diffusion coefficients D_z by the Stokes-Einstein equation⁴³:

$$r_z = k_B T / \{6\pi\eta D_z\} \quad (3)$$

where k_B is the Boltzmann constant, T is the absolute temperature and η is the viscosity of the medium. The following assumptions were made (i) the solutions were sufficiently dilute and sample sizes sufficiently small that non-ideality effects were not significant – i.e. an extrapolation to zero concentration was not necessary. This is reasonable as the non-ideality is due to the low concentration of mucin and small size of teicoplanin, and for translational diffusion, the two main contributory factors to non-ideality – the hydrodynamic and thermodynamic terms - compensate for each other and can even cancel each other out^{45,46}. (ii) the teicoplanin in its monomeric and multi-meric form were quasi-spheroidal and not asymmetric so there was no angular dependence of the measured D_z values on anisotropic rotational diffusion effects – i.e. an extrapolation to zero angles was not necessary.

Intrinsic viscosity measurement

Teicoplanin solutions were analysed using the capillary viscometer AMVn (Anton-Paar, Graz, Austria). This measurement was conducted at a temperature of 25.0 °C based on the rolling ball viscosity method.

With a 1.4mm steel ball moving in a 1.6 mm diameter glass capillary, the flow time of the solvent and solution was then determined. The relative viscosity was calculated from the equation:

$$\eta_{rel} = \frac{\rho \cdot t}{\rho_0 \cdot t_0} = \eta_{sp} + 1 \quad (4)$$

where η_{sp} is the specific viscosity⁴⁷. Then the intrinsic viscosity $[\eta]$ was estimated from the Solomon-Ciuta relation⁴⁸ at a concentration of 10.2 mg/ml:

$$[\eta] \approx \frac{1}{c} \cdot [2\eta_{sp} - 2\ln(\eta_{rel})]^{\frac{1}{2}} \quad (5)$$

Results and Discussion

Hydrodynamic properties of teicoplanin

Figure 2 shows the sedimentation coefficient distribution function $g(s)$ plotted versus $s_{20,w}$, where $g(s)$ is the proportion of sedimentation coefficient values lying within the range of s and $s+ds$. Sedimentation velocity plots obtained using the algorithm SEDFIT for teicoplanin (Figure 2) reveal unimodal behaviour at much higher s -values than expected for monomeric teicoplanin, for concentrations >0.5 mg/ml. Below this concentration separation occurred with bimodality. Figure 3 shows a plot of s vs c for those concentrations where unimodality is still clear. The extrapolated value of ~ 4.65 S is in good agreement with a spherical 18-19-mer of the molar mass of 35400, while the lower extrapolated value of ~ 0.7 S is the predicted value for a spheroidal unimer.

In order to effectively assess the 19-merisation, we sought the application of a chaotropic agent (6M GuHCl) to reduce the solvent effects of water and make teicoplanin more soluble. The s -value of teicoplanin dissolved in 6M GuHCl was ~ 0.7 S and $s_{20,w}$ was (1.17 ± 0.01) S. For the weight-average molar mass, $M_w = (1.75 \pm 0.35)$ kDa (see Figure 4), corresponding the unimer, was obtained. Since teicoplanin was dissolved in the chaotropic agent, the teicoplanin samples did not become 18-19mer over 0-10 mg/mL.




Figure 2. Sedimentation coefficient distribution of teicoplanin A2 at different concentrations from 0-5 mg/mL. The Y-axis ranges are different for each sample because that is clearer to see unimodality for higher concentrations (>0.5 mg/mL) and separation occurring for lower concentrations (<0.5 mg/mL).




Figure 3. Change of apparent sedimentation coefficient ($s_{20,w}$) of teicoplanin A2 with sedimenting concentration, c . Concentrations were corrected for radial dilution. The extrapolated value of ~ 4.65 S is consistent with a spherical 18-19-mer of the molar mass of 35400. The lower extrapolated value of ~ 0.7 S is the predicted value for a spheroidal unimer, which is consistent with the s -value of teicoplanin dissolved in 6M GuHCl, $s_{20,w} = (1.17 \pm 0.01)$ S. Solid line is a standard French curve fit to the data.

Teicoplanin self-association

To determine the weight-average molar masses M_w of teicoplanin, the M^* extrapolation method⁴¹ and hinge point analysis⁴⁰ incorporated in the sedimentation equilibrium-based SEDFIT-MSTAR software⁴⁰ were used. A similar approach was previously used in the analysis of vancomycin²⁹. Rayleigh interference optics provides an accurate record of a sedimentation equilibrium concentration profile $c(r)$ vs r , which means that the local concentration c at the radial position r (cm) is from the rotation centre. $M^*(r)$ is a useful operational point average molar mass parameter. $M^*(r \rightarrow r_b) = M_w$ is the weight average molar mass over the whole macromolecular distribution, where r is the radial position at the cell base. This method is particularly advantageous for polydisperse/ or self-associating systems⁴¹. As an additional check, the “hinge point method” (the value of the point weight average molar mass, $M_w(r)$ at the “hinge point” in the sedimentation equilibrium distribution, i.e. the radial position in the cell where the local concentration $c(r)$ = the original loading concentration) provides another estimate for the whole distribution molar mass M_w ⁴⁰.

When the value of apparent weight average molar masses M_w was extrapolated to zero concentration (1.9 ± 0.1) kDa was obtained, comparable to ($M_1 = 1879.7$ g/mol) of teicoplanin A2-2. This function also gives an approximation of the point weight average molar mass at the hinge point r_{hinge} . At this radial position r_{hinge} the corresponding concentration $c(r)$ is equal to the initial loading concentration c , $M_w(r_{hinge}) = M_w$. The value of (2.7 ± 0.1) kDa was obtained over a monomer molar mass of teicoplanin A2-2 because of self-association.

Regardless of whether using the hinge point method or the M^* method, the change of the apparent weight average molar masses $M_{w,app}$ plateaus from $c = 1$ mg/mL (Figure 4), giving a value of (35400 ± 1000) g/mol. This corresponds to ~ 19 mers in the hinge point method while (33000 ± 1000) g/mol corresponds to ~ 18 mers for the M^* method.




Figure 4. Change of weight average molar mass M_w of teicoplanin with loading concentration derived from sedimentation equilibrium analysed by SEDFIT-MSTAR⁴⁰. Solid square symbols are molar masses $M_{w,app}$ obtained from the M^* method. Solid round symbols are molar masses $M_{w,app}$ obtained from the hinge point method. Solid line is a standard French curve fit to the data. Open triangle symbols are molar masses $M_{w,app}$ of teicoplanin dissolved in 6M GuHCl from the M^* method.

Dynamic light scattering analysis

The self-associative process was confirmed by DLS measurements. Three concentrations were analysed (0.125, 1.25 and 12.5 mg/mL). At 12.5 mg/mL (which corresponds from Figures 3 and 4 to the 18-19 mer species) a particle size distribution of $r_z \sim 3.2\text{nm}$ is observed, and as the concentration is lower the size distribution becomes clearly smaller, indicating dis-assembly towards a smaller molecule (Figure 5).




Figure 5. Distribution of z-average hydrodynamic radii obtained from dynamic light scattering measurements at 20.0°C for teicoplanin in solution at concentrations 12.5, 1.25 and 0.125 mg/mL

Conformational analysis of teicoplanin 18-19mer assembly

The sensitive hydrodynamic conformation probe of intrinsic viscosity $[\eta]$ was used to assess the conformation of the teicoplanin ~ 19mer assembly, reinforced by the sedimentation coefficient, molar mass and (z-averaged) hydrodynamic radius r_z from dynamic light scattering. To avoid possible dissociation effects and to ensure a sufficient flow-time increment, we estimate $[\eta]$ using the Solomon-Ciuta equation (5) at a concentration of 10.2 mg/mL. A value for $[\eta]$ of (3.2 ± 0.1) mL/g.

In order to interpret this in terms of a molecular shape account needs to be taken of the contribution of the swollen specific volume of the assembly in solution v_s (which will be swollen due to a time-averaged association with the surrounding solvent through dynamic hydrogen bonding and other associative processes)⁴³:

$$[\eta] = v \cdot v_s \quad (6)$$

Equation (6) v is the Einstein-Simha shape factor. v_s is likely to be higher than for proteins due to the relatively large proportion of carbohydrates which tends to have a greater affinity for solvent. In *Table 1* values of the shape factor v , and their corresponding ellipsoid of revolution axial ratios a/b were calculated based on either a prolate or oblate model, using the routine ELLIPS1 (Harding et al. 1997) for 3 cases of v_s/\bar{v} , including the (unlikely) case of no swelling $v_s/\bar{v} = 1$. The maximum value for $v_s/v = 2$, which corresponds to the minimum value of $a/b = 1$ (i.e. a sphere, Figure 6), and this seems the most likely scenario.

Table 1. Values of the viscosity shape function v and axial ratio a/b for different values of v_s/\bar{v}

v_s/\bar{v}	v_s (mL/g)	v	(a/b) prolate	(a/b) oblate
1 *	0.64	5.0	4.3	5.4
1.5	0.96	3.3	2.5	2.8
2	1.28	2.5	1	1

*no swelling through dynamic hydration effects. v_s : swollen specific volume; \bar{v} : partial specific volume (0.64 mL/g)




Figure 6. ELLIPS1⁴⁹ representation of the conformation of teicoplanin showing an axial ratio (a/b) = 1: i.e. a sphere

To check this, we use a global fitting approach known as SingleHYDFIT⁵⁰ which combines intrinsic viscosity data with sedimentation coefficient and dynamic light scattering (hydrodynamic radius) data together, along with the molecular weight and partial specific volume. It involves the minimization of a global fitting function (Figure 7). The E2 protocol (ratio of ellipsoid) was chosen and run twice: once with an assumed molar mass equivalent of an 18-mer (33835Da) and once again with an assumed molar mass of 19-mer (35714Da). Delta (Δ) was plotted against axial ratio, where values <1 mean oblate and >1 mean prolate (Figure 7).

The plot shows an optimisation of axial ratios, providing an indication of most likely value to occur. SingleHYDFIT yielded an axial ratio of (1.0 ± 0.0) for both molar masses, suggesting that the supramolecular structure is that of a sphere regardless of whether it is 18- or 19-mer, and confirming the swelling factor of 2 through hydration.




Figure 7. Minimisation function performed by SingleHYDFIT on teicoplanin, using the above hydrodynamic parameters and molar mass consistent with either 18-mer (black square) or 19-mer (red circle). Both plots minimise to 1.0 axial ratio.

Concluding Remarks

In conclusion, based on the matrix-free methods of analytical ultracentrifugation and macromolecular viscometry, teicoplanin appears in phosphate-chloride buffered solution at pH6.8 and $I=0.10$ mol/L as a spheroidal 18-19mer assembly with a swelling ratio in solution of ~ 2 which dissociates at

concentrations < 0.5 mg/mL. This spherical conformation would be consistent with a micellar-like association with the acyl chains on the inside.

There are some similarities with another “last line of defence” glycopeptide antibiotic vancomycin^{29,51}. On the one hand, vancomycin also shows reversible self-associative behaviour above a similar concentration, but this appears to largely truncate to a monomer-dimer only. On the other hand, teicoplanin with its higher degree of glycosylation (two residues in vancomycin versus three residues in teicoplanin) and the lipid chains attached to one of the glcNAc residue self-associates to give a much larger 18-19mer structure in solution, a structure which is broken by the hydrogen and ionic bond disruptive agent 6M GuHCl. As to the nature of this large spherical n-mer association, it could either be due to micellization inspired by its fatty acid chain^{25,26} or it could be due to the non-specific association of its other hydrophobic regions²⁷. Interestingly, *teicoplanin aglycon* without a lipid chain had previously been found to dimerise weakly in solution²⁷. Each or both structural differences may affect the number of building blocks during polymerisation, requiring further research by sedimentation equilibrium experiments using teicoplanin derivatives without either a long acyl chain or sugar units.

In the clinical setting, serum concentrations of teicoplanin are >10 µg/mL or 10 mg/L for intravenous injection¹⁰, resulting in a unimer form of teicoplanin in blood, pH7.4 and I=0.15 mol/L⁵². On the other hand, 10 mg/mL of eye drops¹⁶ would lead to the 18-19 mers on the conjunctiva, which makes it harder for teicoplanin to permeate beyond the cornea. This means that any concentration >0.5 mg/mL has the potential to reduce topical penetration, while at lower concentrations (<10 mg/L or 10 µg/mL) the dose is below the therapeutic concentration and thus ineffective¹⁰. Furthermore if the hydrophobic acyl groups are involved with the binding to the bacterial peptidoglycan, then micellisation would appear to reduce the efficacy as an antibiotic at these higher doses

Additionally, the methods we used can be applied to other members of glycan antibiotics, such as dalbavancin, a lipoglycopeptide with both a fatty acid chain and two sugar residues. Dalbavancin is a second-generation drug developed based on both vancomycin and teicoplanin⁵³. Our combined understanding of the different hydrodynamic behaviour of vancomycin and teicoplanin will help in the development of dalbavancin and other important future-generation antibiotic drugs would result in a better understanding of the structural effects on the aggregational behaviour of some antibiotics. The presence of the third carbohydrate residue and through it reinforcement of the interaction potential through hydrophobic interactions of teicoplanin bears also comparison with a new study using molecular dynamics simulations of the semisynthetic disaccharide antibiotic oritavancin which opens the door for a new generation of antibiotic in the fight against bacterial disease⁵⁴ – and the increasing threat of antimicrobial resistance^{54,55}.

Acknowledgments

We would like to thank Dr. Mary K. Phillips-Jones who originated the idea for this study and for helpful discussions. This work was supported, in part, by the UK Biotechnology and Biological Sciences Research Council [grant number BB/T006404/1].

Author contributions

A.P.C. and S.E.H. supervised the experiments and wrote the paper. T.C. performed the experiments, analysed the data and assisted with the writing of the paper. J.P., R.B.G., V.T.D and G.E.Y. assisted with the analysis of the data.

Data Availability

The datasets used and analysed in the current study are available from the corresponding author upon reasonable request.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to S.E.H.

References

1. Parenti, F., Beretta, G., Berti, M. & Arioli, V. TEICHOMYCINS, NEW ANTIBIOTICS FROM ACTINOPLANES TEICHOMYCETICUS NOV. SP. *J Antibiotics* 31, 276–283 (2006).
2. Barna, J. C. J., Williams, D. H., Stone, D. J. M., Leung, T. W. C. & Doddrell, D. M. Structure elucidation of the teicoplanin antibiotics. *J Am Chem Soc* 106, 4895–4902 (1984).
3. Hunt, A. H., Molloy, R. M., Occolowicz, J. L., Marconi, G. G. & Debono, M. Structure of the major glycopeptide of the teicoplanin complex. *J Am Chem Soc* 106, 4891–4895 (1984).

4. Bernareggi, A., Borghi, A., Borgonovi, M., Cavenaghi, L., Ferrari, P., Vékey, K., Zanol, M. & Zerilli, L. F. Teicoplanin metabolism in humans. *Antimicrob Agents Ch* 36, 1744–1749 (1992).
5. Zanol, M., Cometti, A., Borghi, A. & Lancini, G. C. Isolation and structure determination of minor components of teicoplanin. *Chromatographia* 26, 234–236 (1988).
6. Reynolds, P. E. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. *European Journal of Clinical Microbiology and Infectious Diseases* 8, 943–950 (1989).
7. Zeng, D., Debabov, D., Hartsell, T. L., Cano, R. J., Adams, S., Schuyler, J. A., McMillan, R. & Pace, J. L. Approved Glycopeptide Antibacterial Drugs: Mechanism of Action and Resistance. *Csh Perspect Med* 6, a026989 (2016).
8. Vimberg, V., Gazak, R., Szűcs, Z., Borbás, A., Herczegh, P., Cavanagh, J. P., Zieglerova, L., Závora, J., Adámková, V. & Novotna, G. B. Fluorescence assay to predict activity of the glycopeptide antibiotics. *J Antibiotics* 72, 114–117 (2019).
9. Vimberg, V. Teicoplanin—A New Use for an Old Drug in the COVID-19 Era? *Pharm* 14, 1227 (2021).
10. Wilson, A. P. R. Clinical Pharmacokinetics of Teicoplanin. *Clin Pharmacokinet* 39, 167–183 (2000).
11. Pea, F. Teicoplanin and therapeutic drug monitoring: An update for optimal use in different patient populations. *J Infect Chemother* 26, 900–907 (2020).
12. Pea, F., Brollo, L., Viale, P., Pavan, F. & Furlanut, M. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. *J Antimicrob Chemother* 51, 971–975 (2003).
13. Wenisch, C., Parschalk, B., Hasenhündl, M., Hirschl, A. M. & Graninger, W. Comparison of Vancomycin, Teicoplanin, Metronidazole, and Fusidic Acid for the Treatment of *Clostridium difficile*—Associated Diarrhea. *Clin Infect Dis* 22, 813–818 (1996).
14. Sueke, H., Kaye, S., Wilkinson, M. C., Kennedy, S., Kearns, V., Zheng, Y., Roberts, P., Tuft, S. & Neal, T. Pharmacokinetics of Meropenem for Use in Bacterial Keratitis. *Investigative Ophthalmology Vis Sci* 56, 5731 (2015).
15. Kaye, S. Microbial keratitis and the selection of topical antimicrobials. *Bmj Open Ophthalmol* 1, e000086 (2017).
16. Kaye, S. B., Neal, T., Nicholson, S., Szkurlat, J., Bamber, S., Baddon, A. C., Anderson, S., Seddon, K., Dwyer, N., Lovering, A. M. & Smith, G. Concentration and Bioavailability of Ciprofloxacin and Teicoplanin in the Cornea. *Investigative Ophthalmology Vis Sci* 50, 3176 (2009).

17. Antoniadou, A., Vougioukas, N., Kavouklis, E., Chrissouli, Z. & Giamarellou, H. ration of Teicoplanin (TEC) into Human Aqueous Humor (AH) after Subconjunctival (SCJ) and IV Administration. *Clinical Infectious Diseases* 27, 967 (1998).
18. Zhou, N., Pan, T., Zhang, J., Li, Q., Zhang, X., Bai, C., Huang, F., Peng, T., Zhang, J., Liu, C., Tao, L. & Zhang, H. Glycopeptide Antibiotics Potently Inhibit Cathepsin L in the Late Endosome/Lysosome and Block the Entry of Ebola Virus, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)*. *J Biol Chem* 291, 9218–9232 (2016).
19. Yu, F., Pan, T., Huang, F., Ying, R., Liu, J., Fan, H., Zhang, J., Liu, W., Lin, Y., Yuan, Y., Yang, T., Li, R., Zhang, X., Lv, X., Chen, Q., Liang, A., Zou, F., Liu, B., Hu, F., Tang, X., Li, L., Deng, K., He, X., Zhang, H., Zhang, Y. & Ma, X. Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin L. *Front Microbiol* 13, 884034 (2022).
20. Ceccarelli, G., Alessandri, F., d’Ettorre, G., Borrazzo, C., Spagnolello, O., Oliva, A., Ruberto, F., Mastroianni, C. M., Pugliese, F., Venditti, M. & University, I. C. C.-19 S. G. of S. IS TEICOPLANIN A COMPLEMENTARY TREATMENT OPTION FOR COVID-19? THE QUESTION REMAINS. *Int J Antimicrob Ag* 56, 106029 (2020).
21. Ceccarelli, G., Alessandri, F., Oliva, A., Borrazzo, C., Dell’Isola, S., Ialungo, A. M., Rastrelli, E., Pelli, M., Raponi, G., Turriziani, O., Ruberto, F., Rocco, M., Pugliese, F., Russo, A., d’Ettorre, G. & Venditti, M. The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study). *J Med Virol* 93, 4319–4325 (2021).
22. Leclercq, R., Derlot, E., Eber, M. V., Duval, J. & Courvalin, P. Transferable Vancomycin and Teicoplanin Resistance in *Enterococcus faecium*. *Antimicrobial Agents and Chemotherapy* 33, 10–15 (1989).
23. Butler, M. S., Hansford, K. A., Blaskovich, M. A. T., Halai, R. & Cooper, M. A. Glycopeptide antibiotics: Back to the future. *J Antibiotics* 67, 631–644 (2014).
24. Blaskovich, M. A. T., Hansford, K. A., Butler, M. S., Jia, Z., Mark, A. E. & Cooper, M. A. Developments in Glycopeptide Antibiotics. *Acs Infect Dis* 4, 715–735 (2018).
25. Armstrong, D. W. & Nair, U. B. Capillary electrophoretic enantioseparations using macrocyclic antibiotics as chiral selectors. *Electrophoresis* 12–13, 2331–42 (1997).
26. Wan, H. & Blomberg, L. G. Chiral separation of DL-peptides and enantioselective interactions between teicoplanin and D-peptides in capillary electrophoresis. *Electrophoresis* 18, 943–949 (1997).
27. Bardsley, B., Zerella, R. & Williams, D. H. Aggregation, binding, and dimerisation studies of a teicoplanin aglycone analogue (LY154989). *J Chem Soc Perkin Transactions 2* 0, 598–603 (2002).
28. Harding, S. E. The Svedberg Lecture 2017. From nano to micro: the huge dynamic range of the analytical ultracentrifuge for characterising the sizes, shapes and interactions of

- molecules and assemblies in Biochemistry and Polymer Science. *Eur Biophys J* 47, 697–707 (2018).
29. Phillips-Jones, M. K., Lithgo, R., Dinu, V., Gillis, R. B., Harding, J. E., Adams, G. G. & Harding, S. E. Full hydrodynamic reversibility of the weak dimerization of vancomycin and elucidation of its interaction with VanS monomers at clinical concentration. *Sci Rep* 7, 12697 (2017).
30. Phillips-Jones, M. K., Channell, G., Kelsall, C. J., Hughes, C. S., Ashcroft, A. E., Patching, S. G., Dinu, V., Gillis, R. B., Adams, G. G. & Harding, S. E. Hydrodynamics of the VanA-type VanS histidine kinase: an extended solution conformation and first evidence for interactions with vancomycin. *Sci Rep* 7, 46180 (2017).
31. Dinu, V., Lu, Y., Weston, N., Lithgo, R., Coupe, H., Channell, G., Adams, G. G., Gómez, A. T., Sabater, C., Mackie, A., Parmenter, C., Fisk, I., Phillips-Jones, M. K. & Harding, S. E. The antibiotic vancomycin induces complexation and aggregation of gastrointestinal and submaxillary mucins. *Sci Rep-uk* 10, 960 (2020).
32. NIH, N. C. for B. I. PubChem Compound Summary for CID 16129709, Teicoplanin A2-2. *PubChem* at <<https://pubchem.ncbi.nlm.nih.gov/compound/Teicoplanin-A2-2>>
33. Parenti, F. Structure and mechanism of action of teicoplanin. *Journal of Hospital Infection* 7, 79–83 (1986).
34. Green, A. A. The preparation of acetate and phosphate buffer solutions of known pH and ionic strength. *Journal of the American Chemical Society* 6, 2331–2336 (1933).
35. Tesarová, E., Tuzar, Z., Nesmerák, K., Bosáková, Z. & Gas, B. Study on the aggregation of teicoplanin. *Talanta* 4, 643–53 (2001).
36. Taber, L. E. Study of Vacuum Oven Drying in Official Method for Moisture in Eggs and Egg Products. 63, 941–942 (1980).
37. Kratky, O., Leopold, H. & Stabinger, H. The determination of the partial specific volume of proteins by the mechanical oscillator technique. *Methods in Enzymology* 27, 98–110 (1973).
38. Dam, J. & Schuck, P. Calculating Sedimentation Coefficient Distributions by Direct Modeling of Sedimentation Velocity Concentration Profiles. *Methods Enzymol* 384, 185–212 (2004).
39. Schachman, H. K. *Ultracentrifugation Biochemistry*. (Academic Press: New York, NY, USA; London, UK, 1950).
40. Schuck, P., Gillis, R. B., Besong, T. M. D., Almutairi, F., Adams, G. G., Rowe, A. J. & Harding, S. E. SEDFIT–MSTAR: molecular weight and molecular weight distribution analysis of polymers by sedimentation equilibrium in the ultracentrifuge. *Analyst* 139, 79–92 (2014).

41. Creeth, J. M. & Harding, S. E. Some observations on a new type of point average molecular weight. *Journal of Biochemical and Biophysical Methods* 1, 25–34 (1982).
42. Nobbmann, U., Connah, M., Fish, B., Varley, P., Gee, C., Mulot, S., Chen, J., Zhou, L., Lu, Y., Sheng, F., Yi, J. & Harding, S. E. Dynamic light scattering as a relative tool for assessing the molecular integrity and stability of monoclonal antibodies. *Biotechnology Genetic Eng Rev* 24, 117–128 (2007).
43. Harding, S. E., Sattelle, D. B. & Bloomfield, V. A. *Laser Light Scattering in Biochemistry*. (Royal Society Chemistry, 1992).
44. Provencher, S. W. in *Laser Light Scattering in Biochemistry* (eds. Harding, S. E., Sattelle, D. B. & Bloomfield, V. A.) 92–111 (Royal Society of Chemistry, 1992).
45. Harding, S. E. & Johnson, P. The concentration-dependence of macromolecular parameters. *Biochem J* 231, 543–547 (1985).
46. Harding, S. E. & Johnson, P. Physicochemical studies on turnip-yellow-mosaic virus. Homogeneity, relative molecular masses, hydrodynamic radii and concentration-dependence of parameters in non-dissociating solvents. *Biochem J* 231, 549–555 (1985).
47. Harding, S. E. The intrinsic viscosity of biological macromolecules. Progress in measurement, interpretation and application to structure in dilute solution. *Prog Biophysics Mol Biology* 68, 207–262 (1997).
48. Solomon, O. F. & Ciută, I. Z. Détermination de la viscosité intrinsèque de solutions de polymères par une simple détermination de la viscosité. *Journal of Applied Polymer Science* 6, 683–686 (1962).
49. Harding, S. E., Horton, J. C. & Cölfen, H. The ELLIPS suite of macromolecular conformation algorithms. *Eur Biophys J* 25, 347–359 (1997).
50. Ortega, A. & Torre, J. G. de la. Equivalent Radii and Ratios of Radii from Solution Properties as Indicators of Macromolecular Conformation, Shape, and Flexibility. *Biomacromolecules* 8, 2464–2475 (2007).
51. Hughes, C. S., Longo, E., Phillips-Jones, M. K. & Hussain, R. Characterisation of the selective binding of antibiotics vancomycin and teicoplanin by the VanS receptor regulating type A vancomycin resistance in the enterococci. *Biochimica Et Biophysica Acta Bba - Gen Subj* 1861, 1951–1959 (2017).
52. Covington, A. K. & Robinson, R. A. References standards for the electrometric determination, with ion-selective electrodes, of potassium and calcium in blood serum. *Analytica Chimica Acta* 78, 219–223 (1975).
53. Scheinfeld, N. Dalbavancin: A review for dermatologists. *Dermatology Online Journal* 12, 6 (2006).

54. Olademehin, O. P., Shuford, K. L. & Kim, S. J. Molecular dynamics simulations of the secondary-binding site in disaccharide-modified glycopeptide antibiotics. *Sci Rep* 12, 7087 (2022).
55. Phillips-Jones, M. K. & Harding, S. E. Antimicrobial resistance (AMR) nanomachines—mechanisms for fluoroquinolone and glycopeptide recognition, efflux and/or deactivation. *Biophysical Rev* 10, 347–362 (2018).